Aristotle University Of Thessaloniki (AUTH)
Η υποκλασματική ακτινοθεραπεία με διαμορφούμενης έντασης δέσμες στον καρκίνο του προστάτη
Abstract
dc:descriptionIntroduction: prostate cancer is a disease highly sensitive to radiation therapy (RT) dose per fraction (fr) modifications, specifically to daily dose escalation, a method called hypofractionation. Hypofractionation can electively cause an increase in the total dose distributed to the prostate while a milder increase is observed in the surrounding normal tissues. This in turn can lead shorter treatment duration and potentially better disease control with less toxicity. In this trial we present the results of a comparison in the toxicity profile between a conventionally fractionated RT scheme of 2 Gy/fr to a total dose of 74 Gy and a hypofractionated scheme of 72 Gy with 2.25 Gy/fr. Materials and methods: Patients included in the study had localized prostate cancer (cT1c-T3bN0M0) and were randomly assigned to hypofractionated (72 Gy in 32 fractions, arm1) or conventionally fractionated (74 Gy in 37 fractions, arm2) radiation therapy treatment with Volumetric Arc Therapy technique. The treatment was delivered only to the prostate with or without the seminal vesicles according to physician’s discretion and hormone therapy was optional according to the disease stage and comorbidities. The study’s endpoint was the impact of RT treatment on acute and late adverse events from gastrointestinal (GI) and genitourinary (GU) system which was evaluated by the Radiation Therapy Oncology Group toxicity scale and by quality of life reporting questionnaires (Expanded Prostate index Composite, EPIC)Results:139 patients were recruited in the study, from which 72 received HRT and 67 CRT. At 4 years after the start of the trial, 23 patients (31,9%) from arm 1 developed grade≥ 2 acute genitourinary toxicity and 21 (31,3%) from arm 2 (p=0,79). The corresponding values from gastrointestinal were 15 (20,8%) and 12 (17,9%) (p=0,6). None of the population’s baseline characteristics was associated with acute adverse events from either GU or GI. For late toxicity from GU, 8 patients (11,1%) developed grade≥ 2 symptoms in arm 1 and 7 (10,4%) in arm 2 (p=0,92). late GI toxicity grade≥ 2 was observed in 8 (11,1%) patients in arm 1 and 8 (11,9%) in arm 2 (p=0,88). In multivariate analysis, hormone therapy was significantly associated with late GI events (p=0.016), while acute toxicity from both GU and GI was a prognostic factor of late adverse reaction (p=0.006 and 0.001 respectively). Conclusion: No difference in the acute or late toxicity profile could be identified between hypofractionation and conventional fractionation. Our schedule of 2,25Gy/fr seems safe and tolerable by the patients with acceptable rates of acute and late toxicity.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Alexidis, Petros
- Αλεξίδης, Πέτρος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47787